​

Funding Round

Series C - Prellis Biologics

Series C - Prellis Biologics

Investment Firm

Overview

Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.

Announced Date

Aug 10, 2022

Funding Type

Series C

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

Celesta Capital

Celesta Capital

Celesta Capital is a early_stage_venture and late_stage_venture firm.

Avidity Partners

Avidity Partners

Avidity Partners is a early_stage_venture and late_stage_venture firm.

Participant Investors

8

Investor Name
Participant InvestorCelesta Capital
Participant InvestorBlack Diamond Ventures
Participant InvestorSOSV
Participant InvestorKhosla Ventures
Participant InvestorTrue Ventures

Round Details and Background

Prellis Biologics raised $35000000 on 2022-08-10 in Series C

Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.

Company Funding History

11

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 15, 2021
Series B - Prellis Biologics
2-14.5M
Nov 17, 2023
Series C - Prellis Biologics
2-undefined
Apr 19, 2017
Seed Round - Prellis Biologics
2-120.0K
Sep 13, 2017
Seed Round - Prellis Biologics
4-1.8M

Recent Activity

There is no recent news or activity for this profile.